NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a US-based clinical-stage biotechnology company, announced on Monday that it has named James P Tursi, MD as its new director effective 1 November 2023.
Dr Tursi will also work as a member of the board's Nominating and Corporate Governance Committee.
Presently, Dr Tursi is an executive vice president – Global Research and Development for Endo International plc. He has worked as chief scientific officer US for Ferring Pharmaceuticals, chief medical officer and executive vice president, Research and Development for Antares Pharma Inc, chief medical officer of Aralez Pharmaceuticals Inc., chief medical officer and vice president of Clinical Research and Development for Auxilium Pharmaceuticals, Inc., and served in positions of increasing responsibility at GlaxoSmithKline plc and Procter & Gamble Pharmaceuticals. He has practiced medicine and surgery for more than 10 years and established a medical education company, I Will Pass, that assisted physicians in the process of board certification.
enGene names new chief financial officer and head of Business Development
The American Board of Medical Specialties names new members of the board of directors
MedGenome names new Advisory Board chairman
MentalHealth.com names new Dr Jesse Hanson as new clinical director
Element Biosciences names new director
BD names new executive vice president and chief medical officer
Fuse Oncology names new chief technology officer
Halia Therapeutics names new vice president Regulatory Affairs and new senior medical director
Rivus Pharmaceuticals names new chief medical officer
K36 Therapeutics names new chief medical officer
Kyverna Therapeutics' fifth KYV-101 Investigational New Drug application receives US FDA approval
Nereid Therapeutics names new president and chief executive officer